CANbridge Pharma Overview

  • Founded
  • 2012

Founded
  • Status
  • Public

  • Employees
  • 183

Employees
  • Stock Symbol
  • 01228

Stock Symbol
  • Share Price
  • $0.50

  • (As of Monday Closing)

CANbridge Pharma General Information

Description

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Primary Office
  • Suite 301,3F,Timeloit, No. 17 RongChuang Road
  • Chaoyang District
  • Beijing
  • China
+86 010 0000 0000

CANbridge Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CANbridge Pharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.50 $0.49 $0.46 - $1.28 $211M 424M 19.1K -$1.77

CANbridge Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 821,444 821,444
Revenue 4,826 4,826 1,742 213
EBITDA (164,289) (164,289) (119,470) (30,811)
Net Income (166,795) (166,795) (122,462) (31,503)
Total Assets 140,023 140,023 89,749 12,656
Total Debt 8,174 8,174 7,178 10,044
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CANbridge Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and c
Pharmaceuticals
Beijing, China
183 As of 2021
00000
0000 0000-00-00
00000000 00000

000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
Saint-Julien- en-Genevois, France
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CANbridge Pharma Competitors (56)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genkyotex Corporate Backed or Acquired Saint-Julien- en-Genevois, France 00 000.00 000000&0 000.00
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
000000000 00000000 Formerly VC-backed Guangzhou, China 000.00 00000000000
0000000 0000000000 Formerly VC-backed Shanghai, China 000 00000 00000000 00000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
You’re viewing 5 of 56 competitors. Get the full list »

CANbridge Pharma Patents

CANbridge Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3644062-A4 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Pending 22-Jun-2017 0000000000 0
EP-3644062-A1 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Pending 22-Jun-2017 000000000
US-20210025006-A1 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Pending 22-Jun-2017 000000000000
JP-2020524808-A Methods and kits for predicting esophageal cancer response to anti-erbb3 antibody treatment Pending 22-Jun-2017 G01N33/57407

CANbridge Pharma Executive Team (13)

Name Title Board Seat Contact Info
Qun Xue Ph.D Founder, Chief Executive Officer and Chairman
Glenn Hassan Chief Financial Officer & Chief Business Officer
Richard Gregory Ph.D Acting Chief Scientific Officer & Member of Strategic Advisory Board
Gerald Cox MD Chief Development Strategist and Interim Chief Medical Officer
James Geraghty JD Advisor
You’re viewing 5 of 13 executive team members. Get the full list »

CANbridge Pharma Board Members (4)

Name Representing Role Since
Guangping Gao Ph.D Self Board Member 000 0000
Mark Bamforth CANbridge Pharma Board Member 000 0000
Qun Xue Ph.D CANbridge Pharma Founder, Chief Executive Officer and Chairman 000 0000
You’re viewing 3 of 4 board members. Get the full list »

CANbridge Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CANbridge Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial